Press Releases and Events
PRESS RELEASES
Press Release | September 27, 2021
Press Release | September 15, 2021
CRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
READ MORE
Press Release | September 7, 2021
Crinetics Pharmaceuticals to Participate in September Investor Conferences
READ MORE
Press Release | September 2, 2021
Crinetics Appoints Jeff Knight as Chief Operating Officer
READ MORE
Press Release | August 10, 2021
Crinetics' Second Quarter 2021 Financial Results and Corporate Update
READ MORE
Press Release | August 10, 2021
CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study
READ MORE
Press Release | July 29, 2021
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
READ MORE
Press Release | June 28, 2021
Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
READ MORE
Press Release | June 16, 2021
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
READ MORE
WEBCAST
PRESS RELEASETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
